http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Fri, 17 Jul 2026 12:22:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Press+Releases/Perspective+Therapeutics+Announces+Acceptance+of+VMT-%CE%B1-NET+Data+for+Oral+Presentation+at+the+ESMO+Congress+2026/26783297.html <p align="justify">SEATTLE, July 17, 2026 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective,” the “Company,” “we,” “us,” and “our”) (NYSE AMERICAN: CATX), a radiopharmaceutical development company pioneering advanced treatments for cancers throughout the body, today announced that updated data on the Company’s [212Pb]VMT-α-NET program have been accepted for presentation as detailed below at the European Society of Medical Oncology (ESMO) Congress 2026 taking place October 23 to 27, 2026 in Madrid, Spain. ESMO plans to release further details for regular abstracts on October 19, 2026.</p> <table style="border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black http://www.streetinsider.com/Press+Releases/Perspective+Therapeutics+Announces+Acceptance+of+VMT-%CE%B1-NET+Data+for+Oral+Presentation+at+the+ESMO+Congress+2026/26783297.html Fri, 17 Jul 2026 12:22:00 -0400 A.50205019 A.50216726 CATX O.00064612 O.00706867 O.21612337 http://www.streetinsider.com/Press+Releases/Perspective+Therapeutics+Announces+Acceptance+of+VMT-%CE%B1-NET+Data+for+Oral+Presentation+at+the+ESMO+Congress+2026/26783297.html <p align="justify">SEATTLE, July 17, 2026 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective,” the “Company,” “we,” “us,” and “our”) (NYSE AMERICAN: CATX), a radiopharmaceutical development company pioneering advanced treatments for cancers throughout the body, today announced that updated data on the Company’s [212Pb]VMT-α-NET program have been accepted for presentation as detailed below at the European Society of Medical Oncology (ESMO) Congress 2026 taking place October 23 to 27, 2026 in Madrid, Spain. ESMO plans to release further details for regular abstracts on October 19, 2026.</p> <table style="border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black http://www.streetinsider.com/Press+Releases/Perspective+Therapeutics+Announces+Acceptance+of+VMT-%CE%B1-NET+Data+for+Oral+Presentation+at+the+ESMO+Congress+2026/26783297.html Fri, 17 Jul 2026 12:22:00 -0400 A.50205019 A.50216726 CATX O.00064612 O.00706867 O.21612337 http://www.streetinsider.com/Press+Releases/Perspective+Therapeutics+Announces+Acceptance+of+VMT-%CE%B1-NET+Data+for+Oral+Presentation+at+the+ESMO+Congress+2026/26783297.html <p align="justify">SEATTLE, July 17, 2026 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective,” the “Company,” “we,” “us,” and “our”) (NYSE AMERICAN: CATX), a radiopharmaceutical development company pioneering advanced treatments for cancers throughout the body, today announced that updated data on the Company’s [212Pb]VMT-α-NET program have been accepted for presentation as detailed below at the European Society of Medical Oncology (ESMO) Congress 2026 taking place October 23 to 27, 2026 in Madrid, Spain. ESMO plans to release further details for regular abstracts on October 19, 2026.</p> <table style="border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black http://www.streetinsider.com/Press+Releases/Perspective+Therapeutics+Announces+Acceptance+of+VMT-%CE%B1-NET+Data+for+Oral+Presentation+at+the+ESMO+Congress+2026/26783297.html Fri, 17 Jul 2026 12:22:00 -0400 A.50205019 A.50216726 CATX O.00064612 O.00706867 O.21612337 http://www.streetinsider.com/Press+Releases/Perspective+Therapeutics+Announces+Acceptance+of+VMT-%CE%B1-NET+Data+for+Oral+Presentation+at+the+ESMO+Congress+2026/26783297.html <p align="justify">SEATTLE, July 17, 2026 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective,” the “Company,” “we,” “us,” and “our”) (NYSE AMERICAN: CATX), a radiopharmaceutical development company pioneering advanced treatments for cancers throughout the body, today announced that updated data on the Company’s [212Pb]VMT-α-NET program have been accepted for presentation as detailed below at the European Society of Medical Oncology (ESMO) Congress 2026 taking place October 23 to 27, 2026 in Madrid, Spain. ESMO plans to release further details for regular abstracts on October 19, 2026.</p> <table style="border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black http://www.streetinsider.com/Press+Releases/Perspective+Therapeutics+Announces+Acceptance+of+VMT-%CE%B1-NET+Data+for+Oral+Presentation+at+the+ESMO+Congress+2026/26783297.html Fri, 17 Jul 2026 12:22:00 -0400 A.50205019 A.50216726 CATX O.00064612 O.00706867 O.21612337 http://www.streetinsider.com/Press+Releases/Perspective+Therapeutics+Announces+Acceptance+of+VMT-%CE%B1-NET+Data+for+Oral+Presentation+at+the+ESMO+Congress+2026/26783297.html <p align="justify">SEATTLE, July 17, 2026 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective,” the “Company,” “we,” “us,” and “our”) (NYSE AMERICAN: CATX), a radiopharmaceutical development company pioneering advanced treatments for cancers throughout the body, today announced that updated data on the Company’s [212Pb]VMT-α-NET program have been accepted for presentation as detailed below at the European Society of Medical Oncology (ESMO) Congress 2026 taking place October 23 to 27, 2026 in Madrid, Spain. ESMO plans to release further details for regular abstracts on October 19, 2026.</p> <table style="border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black http://www.streetinsider.com/Press+Releases/Perspective+Therapeutics+Announces+Acceptance+of+VMT-%CE%B1-NET+Data+for+Oral+Presentation+at+the+ESMO+Congress+2026/26783297.html Fri, 17 Jul 2026 12:22:00 -0400 A.50205019 A.50216726 CATX O.00064612 O.00706867 O.21612337 http://www.streetinsider.com/Press+Releases/Perspective+Therapeutics+Announces+Acceptance+of+VMT-%CE%B1-NET+Data+for+Oral+Presentation+at+the+ESMO+Congress+2026/26783297.html <p align="justify">SEATTLE, July 17, 2026 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective,” the “Company,” “we,” “us,” and “our”) (NYSE AMERICAN: CATX), a radiopharmaceutical development company pioneering advanced treatments for cancers throughout the body, today announced that updated data on the Company’s [212Pb]VMT-α-NET program have been accepted for presentation as detailed below at the European Society of Medical Oncology (ESMO) Congress 2026 taking place October 23 to 27, 2026 in Madrid, Spain. ESMO plans to release further details for regular abstracts on October 19, 2026.</p> <table style="border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black http://www.streetinsider.com/Press+Releases/Perspective+Therapeutics+Announces+Acceptance+of+VMT-%CE%B1-NET+Data+for+Oral+Presentation+at+the+ESMO+Congress+2026/26783297.html Fri, 17 Jul 2026 12:22:00 -0400 A.50205019 A.50216726 CATX O.00064612 O.00706867 O.21612337 http://www.streetinsider.com/Globe+Newswire/Perspective+Therapeutics+Announces+Acceptance+of+VMT-%CE%B1-NET+Data+for+Oral+Presentation+at+the+ESMO+Congress+2026/26783297.html <p align="justify">SEATTLE, July 17, 2026 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective,” the “Company,” “we,” “us,” and “our”) (NYSE AMERICAN: CATX), a radiopharmaceutical development company pioneering advanced treatments for cancers throughout the body, today announced that updated data on the Company’s [212Pb]VMT-α-NET program have been accepted for presentation as detailed below at the European Society of Medical Oncology (ESMO) Congress 2026 taking place October 23 to 27, 2026 in Madrid, Spain. ESMO plans to release further details for regular abstracts on October 19, 2026.</p> <table style="border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black http://www.streetinsider.com/Globe+Newswire/Perspective+Therapeutics+Announces+Acceptance+of+VMT-%CE%B1-NET+Data+for+Oral+Presentation+at+the+ESMO+Congress+2026/26783297.html Fri, 17 Jul 2026 12:22:00 -0400 A.50205019 A.50216726 CATX O.00064612 O.00706867 O.21612337 http://www.streetinsider.com/Globe+Newswire/Perspective+Therapeutics+Announces+Acceptance+of+VMT-%CE%B1-NET+Data+for+Oral+Presentation+at+the+ESMO+Congress+2026/26783297.html <p align="justify">SEATTLE, July 17, 2026 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective,” the “Company,” “we,” “us,” and “our”) (NYSE AMERICAN: CATX), a radiopharmaceutical development company pioneering advanced treatments for cancers throughout the body, today announced that updated data on the Company’s [212Pb]VMT-α-NET program have been accepted for presentation as detailed below at the European Society of Medical Oncology (ESMO) Congress 2026 taking place October 23 to 27, 2026 in Madrid, Spain. ESMO plans to release further details for regular abstracts on October 19, 2026.</p> <table style="border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black http://www.streetinsider.com/Globe+Newswire/Perspective+Therapeutics+Announces+Acceptance+of+VMT-%CE%B1-NET+Data+for+Oral+Presentation+at+the+ESMO+Congress+2026/26783297.html Fri, 17 Jul 2026 12:22:00 -0400 A.50205019 A.50216726 CATX O.00064612 O.00706867 O.21612337 http://www.streetinsider.com/Globe+Newswire/Perspective+Therapeutics+Announces+Acceptance+of+VMT-%CE%B1-NET+Data+for+Oral+Presentation+at+the+ESMO+Congress+2026/26783297.html <p align="justify">SEATTLE, July 17, 2026 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective,” the “Company,” “we,” “us,” and “our”) (NYSE AMERICAN: CATX), a radiopharmaceutical development company pioneering advanced treatments for cancers throughout the body, today announced that updated data on the Company’s [212Pb]VMT-α-NET program have been accepted for presentation as detailed below at the European Society of Medical Oncology (ESMO) Congress 2026 taking place October 23 to 27, 2026 in Madrid, Spain. ESMO plans to release further details for regular abstracts on October 19, 2026.</p> <table style="border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black http://www.streetinsider.com/Globe+Newswire/Perspective+Therapeutics+Announces+Acceptance+of+VMT-%CE%B1-NET+Data+for+Oral+Presentation+at+the+ESMO+Congress+2026/26783297.html Fri, 17 Jul 2026 12:22:00 -0400 A.50205019 A.50216726 CATX O.00064612 O.00706867 O.21612337 http://www.streetinsider.com/Globe+Newswire/Perspective+Therapeutics+Announces+Acceptance+of+VMT-%CE%B1-NET+Data+for+Oral+Presentation+at+the+ESMO+Congress+2026/26783297.html <p align="justify">SEATTLE, July 17, 2026 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective,” the “Company,” “we,” “us,” and “our”) (NYSE AMERICAN: CATX), a radiopharmaceutical development company pioneering advanced treatments for cancers throughout the body, today announced that updated data on the Company’s [212Pb]VMT-α-NET program have been accepted for presentation as detailed below at the European Society of Medical Oncology (ESMO) Congress 2026 taking place October 23 to 27, 2026 in Madrid, Spain. ESMO plans to release further details for regular abstracts on October 19, 2026.</p> <table style="border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black http://www.streetinsider.com/Globe+Newswire/Perspective+Therapeutics+Announces+Acceptance+of+VMT-%CE%B1-NET+Data+for+Oral+Presentation+at+the+ESMO+Congress+2026/26783297.html Fri, 17 Jul 2026 12:22:00 -0400 A.50205019 A.50216726 CATX O.00064612 O.00706867 O.21612337 http://www.streetinsider.com/Globe+Newswire/Perspective+Therapeutics+Announces+Acceptance+of+VMT-%CE%B1-NET+Data+for+Oral+Presentation+at+the+ESMO+Congress+2026/26783297.html <p align="justify">SEATTLE, July 17, 2026 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective,” the “Company,” “we,” “us,” and “our”) (NYSE AMERICAN: CATX), a radiopharmaceutical development company pioneering advanced treatments for cancers throughout the body, today announced that updated data on the Company’s [212Pb]VMT-α-NET program have been accepted for presentation as detailed below at the European Society of Medical Oncology (ESMO) Congress 2026 taking place October 23 to 27, 2026 in Madrid, Spain. ESMO plans to release further details for regular abstracts on October 19, 2026.</p> <table style="border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black http://www.streetinsider.com/Globe+Newswire/Perspective+Therapeutics+Announces+Acceptance+of+VMT-%CE%B1-NET+Data+for+Oral+Presentation+at+the+ESMO+Congress+2026/26783297.html Fri, 17 Jul 2026 12:22:00 -0400 A.50205019 A.50216726 CATX O.00064612 O.00706867 O.21612337 http://www.streetinsider.com/Globe+Newswire/Perspective+Therapeutics+Announces+Acceptance+of+VMT-%CE%B1-NET+Data+for+Oral+Presentation+at+the+ESMO+Congress+2026/26783297.html <p align="justify">SEATTLE, July 17, 2026 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective,” the “Company,” “we,” “us,” and “our”) (NYSE AMERICAN: CATX), a radiopharmaceutical development company pioneering advanced treatments for cancers throughout the body, today announced that updated data on the Company’s [212Pb]VMT-α-NET program have been accepted for presentation as detailed below at the European Society of Medical Oncology (ESMO) Congress 2026 taking place October 23 to 27, 2026 in Madrid, Spain. ESMO plans to release further details for regular abstracts on October 19, 2026.</p> <table style="border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black http://www.streetinsider.com/Globe+Newswire/Perspective+Therapeutics+Announces+Acceptance+of+VMT-%CE%B1-NET+Data+for+Oral+Presentation+at+the+ESMO+Congress+2026/26783297.html Fri, 17 Jul 2026 12:22:00 -0400 A.50205019 A.50216726 CATX O.00064612 O.00706867 O.21612337 http://www.streetinsider.com/Corporate+News/Perspective+Therapeutics+names+new+chief+science+officer/26743954.html <p>Perspective Therapeutics (NYSE American: CATX) announced the appointment of Paul Lyne, Ph.D., as Chief Science Officer, replacing co-founder Michael K. Schultz, Ph.D., who has transitioned to the role of Senior Scientific Advisor & Co-Founder as part of a planned move toward retirement.</p><p>Dr. Lyne brings more than 25 years of pharmaceutical and biotechnology experience, including roles in target discovery, drug discovery, early clinical development, and portfolio strategy. He most recently served as Senior Vice President and Head of Oncology Research at Merck KGaA, where he led a global research organization covering cancer cell signaling, immuno-oncology, and antibody-drug conjugates. During his career, http://www.streetinsider.com/Corporate+News/Perspective+Therapeutics+names+new+chief+science+officer/26743954.html Wed, 08 Jul 2026 06:33:44 -0400 CATX http://www.streetinsider.com/Management+Changes/Perspective+Therapeutics+names+new+chief+science+officer/26743954.html <p>Perspective Therapeutics (NYSE American: CATX) announced the appointment of Paul Lyne, Ph.D., as Chief Science Officer, replacing co-founder Michael K. Schultz, Ph.D., who has transitioned to the role of Senior Scientific Advisor & Co-Founder as part of a planned move toward retirement.</p><p>Dr. Lyne brings more than 25 years of pharmaceutical and biotechnology experience, including roles in target discovery, drug discovery, early clinical development, and portfolio strategy. He most recently served as Senior Vice President and Head of Oncology Research at Merck KGaA, where he led a global research organization covering cancer cell signaling, immuno-oncology, and antibody-drug conjugates. During his career, http://www.streetinsider.com/Management+Changes/Perspective+Therapeutics+names+new+chief+science+officer/26743954.html Wed, 08 Jul 2026 06:33:44 -0400 CATX http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Perspective+Therapeutics++For%3A+Jul+01/26720737.html si-local-file:///var/storage/secattach/20260701/26720737.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Perspective+Therapeutics++For%3A+Jul+01/26720737.html Wed, 01 Jul 2026 16:11:00 -0400 CATX O.00064612 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Perspective+Therapeutics++For%3A+Jul+01/26720737.html si-local-file:///var/storage/secattach/20260701/26720737.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Perspective+Therapeutics++For%3A+Jul+01/26720737.html Wed, 01 Jul 2026 16:11:00 -0400 CATX O.00064612 http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13G++Perspective+Therapeutics+++++++++++++++Filed+by%3A+MILLENNIUM+MANAGEMENT+LLC/26715024.html si-local-file:///var/storage/secattach/20260630/26715024.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13G++Perspective+Therapeutics+++++++++++++++Filed+by%3A+MILLENNIUM+MANAGEMENT+LLC/26715024.html Tue, 30 Jun 2026 17:37:00 -0400 CATX O.00064612 http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13G++Perspective+Therapeutics+++++++++++++++Filed+by%3A+MILLENNIUM+MANAGEMENT+LLC/26715024.html si-local-file:///var/storage/secattach/20260630/26715024.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13G++Perspective+Therapeutics+++++++++++++++Filed+by%3A+MILLENNIUM+MANAGEMENT+LLC/26715024.html Tue, 30 Jun 2026 17:37:00 -0400 CATX O.00064612 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Perspective+Therapeutics++For%3A+Jun+01/26578653.html si-local-file:///var/storage/secattach/20260601/26578653.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Perspective+Therapeutics++For%3A+Jun+01/26578653.html Mon, 01 Jun 2026 06:31:00 -0400 CATX O.00064612 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Perspective+Therapeutics++For%3A+Jun+01/26578653.html si-local-file:///var/storage/secattach/20260601/26578653.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Perspective+Therapeutics++For%3A+Jun+01/26578653.html Mon, 01 Jun 2026 06:31:00 -0400 CATX O.00064612 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Perspective+Therapeutics++For%3A+May+27/26558193.html si-local-file:///var/storage/secattach/20260527/26558193.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Perspective+Therapeutics++For%3A+May+27/26558193.html Wed, 27 May 2026 16:20:00 -0400 CATX O.00064612 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Perspective+Therapeutics++For%3A+May+27/26558193.html si-local-file:///var/storage/secattach/20260527/26558193.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Perspective+Therapeutics++For%3A+May+27/26558193.html Wed, 27 May 2026 16:20:00 -0400 CATX O.00064612 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Perspective+Therapeutics++For%3A+May+21/26538043.html si-local-file:///var/storage/secattach/20260522/26538043.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Perspective+Therapeutics++For%3A+May+21/26538043.html Fri, 22 May 2026 06:01:00 -0400 CATX O.00064612 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Perspective+Therapeutics++For%3A+May+21/26538043.html si-local-file:///var/storage/secattach/20260522/26538043.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Perspective+Therapeutics++For%3A+May+21/26538043.html Fri, 22 May 2026 06:01:00 -0400 CATX O.00064612 http://www.streetinsider.com/Press+Releases/Perspective+Therapeutics+to+Present+Data+from+All+Clinical+Programs+at+the+2026+ASCO+Annual+Meeting%2C+including+Findings+from+%5B212Pb%5DVMT01+in+Melanoma/26537121.html <ul><li style="text-align:justify;"><em>One new responder observed in the [</em><em>212</em><em>Pb]VMT01 3.0 mCi monotherapy cohort for a total of two confirmed responses out of seven (29%) treated in this cohort of the Phase 1/2a study in heavily pre-treated melanoma; further data expected in late 2026</em></li><li style="text-align:justify;"><em>[²¹²Pb]PSV359 advanced to Cohort 3 of the Phase 1/2a study in FAP-expressing solid tumors; initial safety findings in lower dose cohorts were Grades 1 and 2 only, with no DLTs and no discontinuation due to adverse events; further data expected in late 2026</em></li><li style="text-align:justify;"><em>Updated [</em><em>212</em><em>Pb]VMT-α-NET interim efficacy (n=25) and safety data (n=68) as of April 17, 2026, were http://www.streetinsider.com/Press+Releases/Perspective+Therapeutics+to+Present+Data+from+All+Clinical+Programs+at+the+2026+ASCO+Annual+Meeting%2C+including+Findings+from+%5B212Pb%5DVMT01+in+Melanoma/26537121.html Thu, 21 May 2026 17:51:00 -0400 A.06822034 A.50205019 A.50216726 CATX O.00064612 O.00706867 O.20026344 O.21612337